HOME >> MEDICINE >> NEWS
Hopkins geneticist discovers mutations in cancer cells that suggest new forms of treatment

Researchers at Johns Hopkins have identified three new genetic mutations in brain tumors, a discovery that could pave the way for more effective cancer treatments.

The Hopkins team, in conjunction with researchers at the J. Craig Venter Institute in Rockville, Md., discovered DNA abnormalities in two tyrosine kinase proteins already known to disrupt normal cell activity and contribute to tumor formation.

The discovery of these mutations is especially significant, the researchers say, because tyrosine kinases can be targeted using pharmaceuticals.

"We picked these proteins to sequence because receptor tyrosine kinases sit on the cell surface where anticancer drugs can get at them," said Gregory J. Riggins, M.D., co-lead author of the study and an associate professor in the Department of Neurosurgery at The Johns Hopkins University School of Medicine.

In the study, published in the October 4th edition of The Proceedings of the National Academy of Sciences, the researchers identified two of the previously unknown mutations in fibroblast growth receptor 1 (FGFR1) and one in platelet derived growth factor receptor alpha (PDGFRA).

FGFR1 and PDGFRA, said Riggins, have been implicated in several other cancers such as colorectal, breast and ovarian cancer, as well as chronic myelogenous leukemia, gastrointestinal stromal tumors and lymphoma.

Riggins and colleagues analyzed a catalog of 518 protein kinase sequences taken from the Human Genome Project. Using high-throughput gene sequencing equipment based at the Venter Institute's Joint Technology Center, they resequenced 20 targeted proteins from tissue samples of brain tumor cells from Hopkins. The cells came from 19 glioblastoma tumors from eight females and 11 males ranging in age from 7 to 77 years. Glioblastomas are malignant tumors of the central nervous system usually found in the cortex of the brain.

Researchers discovered the mutations after comparing the reseq
'"/>

Contact: Eric Vohr
evohr1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
26-Sep-2005


Page: 1 2

Related medicine news :

1. Johns Hopkins begins aggressive screening for superbugs in children
2. Johns Hopkins develops pancreas cancer risk model
3. Hopkins study reveals white blood cells can both hurt and help transplanted kidneys
4. Hopkins scientists link immune response to ghost parasites and severely congested sinuses
5. Hopkins-led study finds that chronic form of depression runs in families
6. Diagnosis and referrals for kidney disease fall well short of need, Johns Hopkins study shows
7. Johns Hopkins Childrens Center to lead largest-ever study on kidney disease in children
8. Hopkins scientists show hallucinogen in mushrooms creates universal mystical experience
9. Johns Hopkins lab scientists tame overactive CF protein
10. Hopkins researchers develop new quick tool to sort out insect bites in children
11. Hopkins scientists use embryonic stem cells, new cues to awaken latent motor nerve repair

Post Your Comments:
(Date:7/7/2015)... ... July 07, 2015 , ... The Immune Deficiency Foundation (IDF) ... community using its IDF ePHR, an electronic personal health record powered by Get ... easily track their health information, including symptoms, diagnoses, medications, infusions and other critical ...
(Date:7/7/2015)... ... 07, 2015 , ... Parents and guardians of teenagers or young adults will ... holistic treatment center for drug and alcohol abuse located in Southwest Michigan. A recently ... shown a significant increase in the “club drug” use among high school seniors. The ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... of telemedicine programs in communities throughout Georgia, announces the launch of the first ... rural communities of Hancock County, GA. The new program will not only provide ...
(Date:7/7/2015)... NH (PRWEB) , ... July ... ... integrated, full-service public relations, marketing, and creative design firm, today announced that ... regional public relations and social media campaign, content strategy, and marketing launch ...
(Date:7/7/2015)... Horsham, PA (PRWEB) , ... July 07, 2015 ... ... seasoned financial executive Ellen Purdy as the company’s new Chief Financial Officer, effective ... financial and leadership experience in companies ranging from a multi-billion dollar, global chemical ...
Breaking Medicine News(10 mins):Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 2Health News:Get Real Health Launches New Mobile App for Immune Deficiency Foundation Patient Community 3Health News:A Forever Recovery Releases New Information on “Club Drugs” and Tips for Parents of Teens and Young Adults 2Health News:Georgia Partnership for TeleHealth prepares to Launch First Ambulance Telemedicine Solution in Georgia 2Health News:TimberNook Selects Calypso Communications for PR, Social Media and Content Strategy 2Health News:Office Practicum Announces new CFO 2
(Date:7/7/2015)... SHENZHEN, China , July 7, 2015 /PRNewswire/ -- ... ), a leading developer, manufacturer and marketer of ... to acquire the remaining stake in Wuhan Dragonbio ... million. Dragonbio is a domestic ... joint and other surgical products. Prior to today,s ...
(Date:7/7/2015)... 2015 EnteroMedics Inc. (NASDAQ: ETRM ), ... technology to treat obesity, metabolic diseases, and other gastrointestinal ... offering of 32,000,000 units. Each unit consists of one share ... purchase one share of common stock at a purchase ... units in the offering would result in them beneficially ...
(Date:7/7/2015)... July 7, 2015 Oasmia ... of drugs within human and veterinary oncology, today ... in the United States , ... leading companion animal therapeutic.      (Logo: ... ) , Paccal Vet-CA1 was ...
Breaking Medicine Technology:Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 2Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 3Mindray Medical to Acquire the Remaining Stake in Wuhan Dragonbio 4EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $16.0 Million Public Offering of Common Stock and Warrants 3Oasmia Pharmaceutical Launches US Brand and Sales Platform 2
Cached News: